KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Receivables - Net: 2010-2025

Historic Receivables - Net for Emergent BioSolutions (EBS) over the last 15 years, with Sep 2025 value amounting to $149.5 million.

  • Emergent BioSolutions' Receivables - Net rose 23.25% to $149.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.5 million, marking a year-over-year increase of 23.25%. This contributed to the annual value of $154.5 million for FY2024, which is 19.11% down from last year.
  • Emergent BioSolutions' Receivables - Net amounted to $149.5 million in Q3 2025, which was up 87.34% from $79.8 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Receivables - Net ranged from a high of $290.1 million in Q2 2023 and a low of $79.8 million during Q2 2025.
  • For the 3-year period, Emergent BioSolutions' Receivables - Net averaged around $181.1 million, with its median value being $191.0 million (2023).
  • Per our database at Business Quant, Emergent BioSolutions' Receivables - Net spiked by 65.77% in 2023 and then crashed by 59.35% in 2025.
  • Emergent BioSolutions' Receivables - Net (Quarterly) stood at $278.9 million in 2021, then tumbled by 42.92% to $159.2 million in 2022, then grew by 19.97% to $191.0 million in 2023, then declined by 19.11% to $154.5 million in 2024, then climbed by 23.25% to $149.5 million in 2025.
  • Its last three reported values are $149.5 million in Q3 2025, $79.8 million for Q2 2025, and $203.7 million during Q1 2025.